McIntosh C H, Bakich V, Bokenfohr K, DiScala-Guenot D, Kwok Y N, Brown J C
Department of Physiology, University of British Columbia, Vancouver, Canada.
Regul Pept. 1988 Jun;21(3-4):205-18. doi: 10.1016/0167-0115(88)90003-1.
Administration of cysteamine (beta-mercaptoethylamine; 2-aminoethanethiol) to rats has been shown to decrease the levels of somatostatin-like immunoreactivity (SLI) in the gastrointestinal tract and pancreas but its mode of action is unclear. In the current study the effect of cysteamine on gastrointestinal and pancreatic SLI has been studied using two antisera with different regional specificities. In addition, the in vitro effect of cysteamine on SS-14 and SS-28 has been studied by high-performance liquid chromatography (HPLC). Characterization of the two antisera (AS 26.3.2 and AS 1001) with a range of analogs of SS-14 revealed that both were directed against the midportion of the molecule but that AS 1001 was also sensitive to changes at the N- and C-termini. Tissue extracts from cysteamine-treated rats measured with AS 26.3.2 showed no significant change for the stomach, jejunum or pancreas but duodenal levels were reduced. With AS 1001 SLI levels were reduced in all tissues. Gel permeation chromatography of stomach extracts measured with AS 1001 showed a reduction in both SS-14 and SS-28. With AS 26.3.2 an increase in SLI eluting prior to the SS-14 peak occurred explaining why no significant reduction in total SLI was detected. With duodenal extracts the elution profiles with AS 1001 reflected the large reduction in total SLI whereas with AS 26.3.2 a smaller reduction occurred. Both SS-14 and SS-28 were reduced. HPLC analysis of SS-14 and SS-28 following incubation with cysteamine in vitro showed a time-dependent decrease in both somatostatin species with absorbance at 280 nm was measured. New peptide peaks which developed were not all detectable by radioimmunoassay with either antibody. The results suggest that cysteamine causes a change in the structure of somatostatin which probably first involves a reduction of the disulphide bridge and then the N- and C-terminal regions of the molecule thus making it unmeasurable by antisera sensitive to changes in these regions.
给大鼠施用半胱胺(β-巯基乙胺;2-氨基乙硫醇)已显示可降低胃肠道和胰腺中生长抑素样免疫反应性(SLI)的水平,但其作用方式尚不清楚。在当前研究中,使用两种具有不同区域特异性的抗血清研究了半胱胺对胃肠道和胰腺SLI的影响。此外,通过高效液相色谱(HPLC)研究了半胱胺对SS - 14和SS - 28的体外作用。用一系列SS - 14类似物对两种抗血清(AS 26.3.2和AS 1001)进行表征发现,两者均针对分子的中部,但AS 1001对N端和C端的变化也敏感。用AS 26.3.2测量半胱胺处理大鼠的组织提取物,胃、空肠或胰腺未显示出显著变化,但十二指肠水平降低。使用AS 1001时,所有组织中的SLI水平均降低。用AS 1001测量胃提取物的凝胶渗透色谱显示SS - 14和SS - 28均减少。使用AS 26.3.2时,在SS - 14峰之前洗脱的SLI增加,这解释了为何未检测到总SLI的显著降低。对于十二指肠提取物,AS 1001的洗脱曲线反映了总SLI的大幅降低,而使用AS 26.3.2时降低幅度较小。SS - 14和SS - 28均减少。体外将半胱胺与SS - 14和SS - 28一起孵育后的HPLC分析显示,两种生长抑素种类均呈时间依赖性降低,并测量了280 nm处的吸光度。新出现的肽峰并非都能用两种抗体中的任何一种通过放射免疫测定法检测到。结果表明,半胱胺导致生长抑素结构发生变化,这可能首先涉及二硫键的减少,然后是分子的N端和C端区域,从而使其无法被对这些区域变化敏感的抗血清检测到。